Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic ...

This is promising news.

In a small clinical trial, a single dose of a psychedelic drug paired with psychotherapy produced rapid antidepressant ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

People taking DMT tended to experience significant relief from their depression for up to three months, the researchers found ...

A Phase IIa clinical trial finds that a single, brief dose of DMT (from ayahuasca) provides rapid and lasting relief for depression.

"A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, ...

The keto diet might help ease depression in people who aren't responding to antidepressants, a new study reports. People ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

In clinical trials, almost 500 depression patients who were resistant to current treatments were given therapy that stimulated their vagus nerve. The majority of these patients had such serious ...

Working out can boost mental health. To reap the most benefits, it should be structured, supervised and contain a social ...

San Juan Capistrano, California / Syndication Cloud / February 12, 2026 / Mission Prep Key Takeaways Teen depression ...